Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria | NEJM
Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcut…